近期，全球中枢神经（CNS）赛道的霸主渤健（Biogen）一纸声明，彻底砍掉所有依托腺相关病毒（AAV）外壳的基因疗法管线。其实早在2023年那次“大扫除”式的研发版图重构中，公司就已悄悄把AAV方案踢出核心梯队，人力、资金逐步向更被看好的新方向倾斜。来源：fiercebiotechBiogen的离场只是多米诺骨牌的第一张。当基因治疗赛道由“高烧”转入“退烧”周期，跨国巨头们接连给AAV踩下急刹。...
Source Link近期，全球中枢神经（CNS）赛道的霸主渤健（Biogen）一纸声明，彻底砍掉所有依托腺相关病毒（AAV）外壳的基因疗法管线。其实早在2023年那次“大扫除”式的研发版图重构中，公司就已悄悄把AAV方案踢出核心梯队，人力、资金逐步向更被看好的新方向倾斜。来源：fiercebiotechBiogen的离场只是多米诺骨牌的第一张。当基因治疗赛道由“高烧”转入“退烧”周期，跨国巨头们接连给AAV踩下急刹。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.